Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions Purpose of reviewWhile people with HIV (PWH) are living longer due to advances in antiretroviral therapy, recent data have demonstrated an increased risk of cardiovascular disease (CVD) among this population. This increased risk is thought to be due to both traditional (for example, smoking, diabetes) and HIV-specific (for example, inflammation, persistent immune activation) risk factors. This review focuses on the potential for statin therapy to mitigate this increased risk.Recent findingsSeveral randomized clinical trials have demonstrated that statins, a class of lipid-lowering medications, are effective as a primary CVD prevention strategy among people without HIV. Among PWH, statins have been shown to lower cholesterol, exert immunomodulatory effects, stabilize coronary atherosclerotic plaque, and even induce plaque regression.SummaryPrevention of CVD among the aging population of people with controlled, but chronic, HIV is vital. Data exploring primary prevention in this context are thus far limited. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is ongoing; this trial will inform the field by investigating the effects of pitavastatin calcium as a primary prevention strategy for major adverse cardiovascular events among PWH on antiretroviral therapy (ART) at low-to-moderate traditional CVD risk. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/statins-for-primary-cardiovascular-disease-prevention-among-people-6OakQqLpmA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/coh.0000000000000752
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewWhile people with HIV (PWH) are living longer due to advances in antiretroviral therapy, recent data have demonstrated an increased risk of cardiovascular disease (CVD) among this population. This increased risk is thought to be due to both traditional (for example, smoking, diabetes) and HIV-specific (for example, inflammation, persistent immune activation) risk factors. This review focuses on the potential for statin therapy to mitigate this increased risk.Recent findingsSeveral randomized clinical trials have demonstrated that statins, a class of lipid-lowering medications, are effective as a primary CVD prevention strategy among people without HIV. Among PWH, statins have been shown to lower cholesterol, exert immunomodulatory effects, stabilize coronary atherosclerotic plaque, and even induce plaque regression.SummaryPrevention of CVD among the aging population of people with controlled, but chronic, HIV is vital. Data exploring primary prevention in this context are thus far limited. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is ongoing; this trial will inform the field by investigating the effects of pitavastatin calcium as a primary prevention strategy for major adverse cardiovascular events among PWH on antiretroviral therapy (ART) at low-to-moderate traditional CVD risk.

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Sep 16, 2022

References

  • Future challenges for clinical care of an ageing population infected with HIV: a modelling study
  • Projections of noncommunicable disease and healthcare costs among HIV-positive persons in Italy and the U.S.A: a modelling study
  • Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV
  • Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
  • Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies
  • Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
  • HIV infection and the risk of acute myocardial infarction
  • Global burden of atherosclerotic cardiovascular disease in people living with HIV
  • Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men
  • Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection
  • Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients
  • Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women
  • Arterial inflammation in patients With HIV
  • Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men
  • Macrophage-specific arterial infiltration relates to plaque type and immune activation in HIV
  • Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation
  • Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection
  • Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care
  • Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients
  • Increased systemic inflammation and gut permeability among women with treated HIV infection in rural Uganda
  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
  • Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis
  • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
  • Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials
  • Trends in utilization of statin therapy and contraindicated statin use in HIV--infected adults treated with antiretroviral therapy from 2007 through 2015
  • A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients
  • Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
  • Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
  • A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
  • Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
  • Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial
  • Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial
  • Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy
  • Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy
  • Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy
  • High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial
  • Down regulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load
  • Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV
  • Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients
  • 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors
  • Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial
  • Serial coronary CT angiography–verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention
  • Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound: the TOGETHAR Trial
  • Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome
  • Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography
  • Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study
  • Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the new age II pilot study
  • Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study)
  • Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial
  • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
  • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
  • Statins and the vascular endothelial inflammatory response
  • Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase
  • HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo
  • Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
  • Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36
  • Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice
  • Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
  • Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses
  • Statins as a newly recognized type of immunomodulator
  • Influence of statins on MHC class I expression
  • Statins induce regulatory T cell recruitment via a CCL1 dependent pathway
  • Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells
  • Inhibition of monocyte chemotactic protein-1 synthesis by statins
  • Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages
  • Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion
  • Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors
  • Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies
  • Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
  • Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy
  • Comparative effectiveness and toxicity of statins among HIV-infected patients
  • Statin use is associated with incident diabetes mellitus among patients in the hiv outpatient study
  • Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death
  • Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients
  • Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy
  • Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial
  • Evaluation of the anti-HIV activity of statins
  • The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
  • Statins inhibit HIV-1 infection by down-regulating Rho activity
  • Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication
  • Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1
  • Statins could be used to control replication of some viruses, including HIV-1
  • Statins disrupt CCR5 and RANTES expression levels in CD4 (+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1
  • Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection
  • Statin utilization and recommendations among HIV- and HCV-infected veterans: a cohort study
  • 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque
  • Cardiovascular risk prediction functions underestimate risk in HIV infection
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
  • An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
  • The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: external validation in a diverse cohort of people living with HIV
  • Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
  • Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers
  • Statins in HIV-infected patients: potential beneficial effects and clinical use
  • Leveraging a landmark trial of primary cardiovascular disease prevention in human immunodeficiency virus: introduction from the REPRIEVE coprincipal investigators